Non Small-Cell Lung Cancer in a 15-Year-Old Nonsmoker  by Koodiyedath, Bindu et al.
e12 Journal of Thoracic Oncology  •  Volume 7, Number 9, September 2012
CASE HISTORY
A previously healthy 15-year old presented to the Childrens 
Hospital Emergency Department with spontaneous pneumo-
thorax, which recurred after needle thoracocentesis. Review of 
plain chest radiograph suggested mediastinal lymphadenopathy 
with compression of the left main bronchus (Fig. 1). Computed 
tomography of the chest confirmed these findings and also dem-
onstrated an endobronchial left main bronchus mass (Fig. 2).
Because of the patients age, a differential diagnosis of 
lymphoma or germ cell tumor was formulated, but workup 
including tumor markers and bone-marrow examination was 
negative. Initial flexible bronchoscopy was not diagnostic. 
Rigid bronchoscopy and transcarinal tru-cut biopsy were 
subsequently performed by the adult thoracic surgeons and 
confirmed a poorly differentiated high-grade epithelial malig-
nancy. Extensive immunohistochemistry along with tumor cell 
morphology and the presence of admixed reactive lymphoid 
cells supported a diagnosis of lymphoepithelial carcinoma 
(Fig. 3). Epstein Barr virus encoded RNA study and endo-
thelial growth factor receptor mutation screen were negative.
TREATMENT
In view of the extreme rarity of nonsmall-cell lung 
cancer in this age group, and to ensure the appropriate provi-
sion of site- and age-specific expertise, the patients care was 
provided jointly by pediatric and adult oncologists. Because 
of the position, distribution, and volume of the tumor mass, 
neither surgery nor radical radiotherapy were possible at diag-
nosis. A decision was made to offer primary chemotherapy 
followed by restaging with the intention of consolidating any 
response with loco-regional radiotherapy.
Combination chemotherapy with gemcitabine and 
platinum-based chemotherapy was considered to be most 
appropriate, with cisplatin chosen over carboplatin in view 
of reported survival advantage,1 the patients young age, and 
normal renal function. Gemcitabine was chosen as the most 
appropriate drug to combine with cisplatin in view of the 
absence of adenocarcinoma or large-cell histology.2
Chemotherapy was given once every 3 weeks (gem-
citabine 1250mg/m2 day 1 and day 8, cisplatin 80mg/m2 day 1). 
Disease was stable after two courses. A clear major response 
was seen after course four, maintained after six courses.
Hypofractionated radiotherapy (55 Gy in 20 fractions) 
was given to consolidate the excellent response to chemother-
apy. This was complicated by grade 3 esophagitis. The patient 
is currently in remission 28 months after presentation.
DISCUSSION
This case report describes an unusual presentation of a 
rare condition in the teenage and young adult (TYA) popula-
tion. Accurate diagnosis required close liaison between adult 
and pediatric surgical teams and the input of site-specific 
pathology expertise. Through close cooperation between 
pediatric and adult services, the patient received high-quality, 
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FIGURE 1. Plain chest radiograph demonstrating left-sided 
pneumothorax and bulky left mediastinum.
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age-appropriate care delivered jointly by age- and site- specific 
experts in line with national guidance.3
Although there is a rise in the incidence of epithe-
lial tumors in the TYA age range, lung cancer remains an 
extremely rare diagnosis in this group. Only three other 
patients aged younger than 16 years have been reported to 
the Oxford cancer registry with a diagnosis of nonsmall-
cell lung cancer since 2001 (C. Stiller, personal communi-
cation, 2011).
Lymphoepithelial cancer is an unusual primary lung 
cancer, recognized to occur most frequently in younger 
nonsmokers. It is seen most commonly in Asian populations.4 
Among Asian patients, there is a recognized association with 
Epstein Barr virus infection, although this was not identified 
in a small cohort of Western patients.4,5 Lymphoepithelial can-
cer is recognized as being more chemosensitive than many pri-
mary lung cancers, and long-term survival has been reported 
after combination chemoradiotherapy for locally advanced 
disease.4
Contrary to much of the literature suggesting poorer 
outcome for TYAs with epithelial cancers,6,7 this patient has 
had an encouraging response to treatment and remains in 
remission. Prognostic uncertainty has, however, resulted in 
significant psychological morbidity and the patient continues 
to receive support from the TYA psychosocial multidisci-
plinary team.
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FIGURE 3.  Biopsy (original magnification × 400, haematoxylin 
& eosin stain) showing lymphoid rich background and pleo-
morphic poorly defined epithelioid/polygonal cells with bland 
eosinophilic cytoplasm, somewhat vesicular nuclei, and promi-
nent nucleoli (arrowed). Immunohistochemistry showed weak 
cytokeratin (MNF116, CK5/6) and EMA reactivity. No reactivity 
was seen with other keratins (AE1AE3, CAM5.2). Other markers 
targeting germ cell, lymphoid, and soft tissue neoplasia were 
negative.
FIGURE 2.  Computed tomography thorax demonstrating mediastinal adenopathy (mediastinal window, white arrow) and an 
endobronchial mass in the left main bronchus (lung window, black arrow).
